Core Viewpoint - The announcement highlights that the company Shijiazhuang Pharmaceutical Group has received approval from the National Medical Products Administration of China for three active pharmaceutical ingredients, indicating a significant milestone in expanding its product offerings in the market [1] Group 1: Product Approvals - The three approved active pharmaceutical ingredients are Fenofibrate, Fenofibric Acid, and Sodium Phosphate of Levofloxacin, with the latter being the third domestic company to receive such approval [1] - Fenofibrate and Fenofibric Acid are primarily used for treating hyperlipidemia and hypercholesterolemia, as well as lowering triglyceride levels in patients with severe hypertriglyceridemia [1] - Sodium Phosphate of Levofloxacin is mainly used for treating severe amoebic infections of the intestines and liver, as well as for preventing infections caused by anaerobic bacteria during surgical procedures [1]
石四药集团(02005.HK)：非诺贝特等3个原料药获批准登记成为在上市制剂使用的原料药